Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 12Salivary Gland Neoplasms 1Prostate Adenocarcinoma 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 3lenvatinib 3gallium 68 PSMA-11 2apatinib 2Protons 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2tislelizumab 1regorafenib 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1abemaciclib 1Tretinoin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Adenoid Cystic × Glutamate Carboxypeptidase II × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡